TY - JOUR
T1 - Dyslipidemias associated with endocrine disorders: a position statement of the working group of the nutrition hormones and metabolism club of the italian society of endocrinology (SIE)
AU - Muscogiuri, G
AU - Albertelli, M
AU - Arnaldi, G
AU - Barrea, L
AU - Bellastella, G
AU - Bonomi, M
AU - CAPUTO, Marina
AU - Caprio, M
AU - Cignarelli, A
AU - Di, Gioia L
AU - Frasca, F
AU - FERRARI, DANIELE
AU - Gambineri, A
AU - Gasco, V
AU - Gatto, F
AU - Giandalia, A
AU - Giordano, R
AU - Infante, M
AU - Isidori, A
AU - Malandrino, P
AU - Occhi, G
AU - Pivonello, R
AU - Prencipe, N
AU - PRODAM, Flavia
AU - Simeoli, C
AU - Verde, L
AU - Vignozzi, L
AU - Cannavò, S
AU - Giorgino, F
AU - Colao, A
AU - Aimaretti, G
AU - Ferone, D
AU - Perrini, S
PY - 2026
Y1 - 2026
N2 - Purpose Dyslipidemias are highly prevalent metabolic disturbances and represent a major driver of atherosclerotic cardio-vascular disease. Beyond primary forms, numerous endocrine diseases induce secondary dyslipidemias that substantially modify lipid metabolism and contribute to cardiometabolic risk. This Position Statement of the Nutrition Hormones and Metabolism Club of the Italian Society of Endocrinology (SIE) aims to provide an updated, evidence-based synthesis of the pathophysiology, biochemical profile, and clinical impact of dyslipidemias associated with endocrine disorders.
Methods A comprehensive review of current literature was performed, integrating epidemiological, mechanistic, and clinical data on lipid alterations across major endocrine diseases. Expert consensus was used to interpret evidence and formulate recommendations for clinical practice.
Results Distinct and disease-specific dyslipidemic patterns were identified across conditions involving the hypothalamic–pituitary, thyroid, adrenal, gonadal, and GH/IGF-1 axes. Disorders such as acromegaly, growth hormone deficiency, hypo-thyroidism, hyperthyroidism, Cushing’s syndrome, male and female hypogonadism, congenital adrenal hyperplasia, and polycystic ovary syndrome exhibit characteristic lipid abnormalities driven by hormonal dysregulation. These alterations contribute to increased cardiometabolic risk yet are frequently underrecognized and suboptimally managed. Early identification and tailored intervention may significantly improve outcomes.
Conclusion Endocrine-related dyslipidemias represent a clinically relevant but often overlooked contributor to cardiovascular risk. By summarizing current evidence and expert perspectives, this Position Statement aims to support clinicians in improving diagnosis, risk stratification, and management of lipid disorders associated with endocrine diseases, fostering a multidisciplinary approach to cardiometabolic prevention.
AB - Purpose Dyslipidemias are highly prevalent metabolic disturbances and represent a major driver of atherosclerotic cardio-vascular disease. Beyond primary forms, numerous endocrine diseases induce secondary dyslipidemias that substantially modify lipid metabolism and contribute to cardiometabolic risk. This Position Statement of the Nutrition Hormones and Metabolism Club of the Italian Society of Endocrinology (SIE) aims to provide an updated, evidence-based synthesis of the pathophysiology, biochemical profile, and clinical impact of dyslipidemias associated with endocrine disorders.
Methods A comprehensive review of current literature was performed, integrating epidemiological, mechanistic, and clinical data on lipid alterations across major endocrine diseases. Expert consensus was used to interpret evidence and formulate recommendations for clinical practice.
Results Distinct and disease-specific dyslipidemic patterns were identified across conditions involving the hypothalamic–pituitary, thyroid, adrenal, gonadal, and GH/IGF-1 axes. Disorders such as acromegaly, growth hormone deficiency, hypo-thyroidism, hyperthyroidism, Cushing’s syndrome, male and female hypogonadism, congenital adrenal hyperplasia, and polycystic ovary syndrome exhibit characteristic lipid abnormalities driven by hormonal dysregulation. These alterations contribute to increased cardiometabolic risk yet are frequently underrecognized and suboptimally managed. Early identification and tailored intervention may significantly improve outcomes.
Conclusion Endocrine-related dyslipidemias represent a clinically relevant but often overlooked contributor to cardiovascular risk. By summarizing current evidence and expert perspectives, this Position Statement aims to support clinicians in improving diagnosis, risk stratification, and management of lipid disorders associated with endocrine diseases, fostering a multidisciplinary approach to cardiometabolic prevention.
UR - https://iris.uniupo.it/handle/11579/231598
U2 - 10.1007/s40618-026-02862-y
DO - 10.1007/s40618-026-02862-y
M3 - Article
SN - 1121-1369
JO - JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. SUPPLEMENT
JF - JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. SUPPLEMENT
ER -